Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)

AIMS: To evaluate the short‐term cost‐effectiveness of insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100) from a Canadian public healthcare payer perspective in patients with type 2 diabetes (T2D) who are at high risk of cardiovascular events and hypoglycaemia. MATERIALS AN...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: Pollock, Richard F., Heller, Simon, Pieber, Thomas R., Woo, Vincent, Gundgaard, Jens, Hallén, Nino, Luckevich, Maria, Tutkunkardas, Deniz, Zinman, Bernard
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6618053/
https://ncbi.nlm.nih.gov/pubmed/30924579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13730
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados